Development and Validation of a New Nomogram for Predicting Medication Nonadherence Risk in a Chinese Hyperlipidemia Population

针对中国高脂血症人群,开发和验证一种预测药物不依从性风险的新列线图

阅读:2

Abstract

PURPOSE: This study aimed to explore the factors influencing medication adherence and develop a medication nonadherence risk nomogram in a Chinese population with hyperlipidemia. METHODS: This prospective intervention study was conducted in Beijing from November 2020 to October 2021. Medication adherence was determined according to the 9-question scale and nonadherence patients were intervened by pharmacists and followed up for 3 months. Multivariate logistic regression was used to analyze the risk factors of medication nonadherence, and then a nomogram model was established. The concordance index (C-index), area under the curve (AUC) was used to evaluate the accuracy of the prediction model. The decision curve analysis (DCA) and clinical impact plot analysis were employed to further evaluate the clinical effectiveness of the nomogram. RESULTS: A total of 685 patients were included for analysis. The rate of medication nonadherence was 238 patients (34.75%). Post-intervention, the average score of medication adherence increased from 20.75±8.01 to 29.90±6.93 (p < 0.001). And the number of patients with TC, TG, LDL-C, and HDL-C reaching the standard was 264 (62.86%), 201 (47.43%), 318 (78.52%), and 377 (96.71%), respectively. Five predictors including the course of hyperlipidemia (OR=2.957, 95% CI 1.168-7.488), following the doctor's advice to visit (OR=2.757, 95% CI 1.389-5.472), use of medications empirically (OR=1.189, 95% CI 1.188-2.786), physical exercise (OR=0.399, 95% CI 0.205-0.776) and lifestyle compliance (OR=0.910, 95% CI 0.839-0.988) were identified to build the nomogram model. The AUC was 0.927 and C-index was 0.87. CONCLUSION: Patients with hyperlipidemia displayed low medication adherence which pharmaceutical interventions can improve. We developed and validated a nomogram model to facilitate the individual medication nonadherence risk prediction in hyperlipidemia patients. LIMITATION: First, using the cut-off value of 27 for adherence assessment in the adherence questionnaire, criterion validity was not enough good to validly screen a patient with nonadherence to medication. Second, our study may have unmeasured confounding variables, which could bias the results. Third, owing to the lack of external validation in this study, it may have some limitations in extrapolation. Fourth, the questionnaire was assessed by self-report measures.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。